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ttp://dx.doi.org/10.1016/j.ajpath.2013.05.022Hypoplastic left heart syndrome (HLHS) is a severe cardiac malformation characterized by left ventricle
(LV) hypoplasia and abnormal LV perfusion and oxygenation. We studied hypoxia-associated injury in
fetal HLHS and human pluripotent stem cells during cardiac differentiation to assess the effect of
microenvironmental perturbations on fetal cardiac reprogramming. We studied LV myocardial samples
from 32 HLHS and 17 structurally normal midgestation fetuses. Compared with controls, the LV in fetal
HLHS samples had higher nuclear expression of hypoxia-inducible factor-1a but lower angiogenic
growth factor expression, higher expression of oncogenes and transforming growth factor (TGF)-b1,
more DNA damage and senescence with cell cycle arrest, fewer cardiac progenitors, myocytes and
endothelial lineages, and increased myoﬁbroblast population (P < 0.05 versus controls). Smooth
muscle cells (SMCs) had less DNA damage compared with endothelial cells and myocytes. We recapit-
ulated the fetal phenotype by subjecting human pluripotent stem cells to hypoxia during cardiac
differentiation. DNA damage was prevented by treatment with a TGF-b1 inhibitor (P < 0.05 versus
nonhypoxic cells). The hypoplastic LV in fetal HLHS samples demonstrates hypoxia-inducible factor-1a
up-regulation, oncogene-associated cellular senescence, TGF-b1eassociated ﬁbrosis and impaired
vasculogenesis. The phenotype is recapitulated by subjecting human pluripotent stem cells to hypoxia
during cardiac differentiation and rescued by inhibition of TGF-b1. This ﬁnding suggests that hypoxia
may reprogram the immature heart and affect differentiation and development. (Am J Pathol 2013,
183: 720e734; http://dx.doi.org/10.1016/j.ajpath.2013.05.022)Supported by an Ontario Ministry of Economic Development and
Innovation GL2 award and SickKids Labatt Family Heart Centre Innova-
tion Funds.Physiologic adaptations that enable a fetus to tolerate
a period of intrauterine deprivation may result in permanent
reprogramming of the pathways of organ development, with
pathologic consequences in later life.1 The nature of this
permanent reprogramming is poorly understood, particu-
larly the interaction between environmental factors and
developmental pathways. Several cardiac malformations are
characterized by poor growth of cardiac chambers and major
blood vessels, which impairs organ perfusion and oxygen-
ation. An example is hypoplastic left heart syndrome
(HLHS) in which the left-sided structures are poorly
developed likely due to an underlying genetic defect. As
a result, better oxygenated blood from the inferior vena cavastigative Pathology.
.fails to shunt right to left at the foramen ovale to reach the
left ventricle (LV) and the aorta. Instead, the aorta and
coronaries receive more deoxygenated blood by retrograde
ﬂow from the descending aorta into the hypoplastic
ascending aorta to supply the head vessels and the coro-
naries. This results not only in lower oxygen saturation but
also in lower coronary blood ﬂow, further reducing oxygen
delivery to the myocardium.2 The fetal blood oxygen
dissociation curve is steep, and a difference of even 2 to 3
Senescence in Fetal HLHSmm Hg in Po2 can produce a change in oxygen content of as
much as 1 to 1.5 mL/dL. We hypothesized that the reduced
blood ﬂow through the LV and the oxygenation and
perfusion abnormalities in the coronary circulation that are
critical for vascular growth may reprogram growth signals
and reversibly or irreversibly impair future ventricular
growth potential.3
We analyzed growth and differentiation pathways in
HLHS by studying human fetal hearts during the second
trimester, which is the most critical period for cardiac growth.
We also studied human pluripotenteembryonicestem cells
(hPSCs), during cardiac differentiation to deﬁne the mecha-
nisms of hypoxia-induced injury in fetal stage cardiac cells.
Because the process of cardiac differentiation of hPSCs
mimics the process of cardiogenesis, hPSCs provide
a potential in vitro cellular model to study the effect of
prenatal factors on cardiac differentiation.4,5 Overall, we
found signiﬁcant DNA damage accumulation and prema-
ture senescence, transforming growth factor (TGF)-b1e
associated ﬁbrosis, and impaired angiogenesis in fetal
HLHS and in vitro in hPSC-derived cardiac lineages sub-
jected to prolonged hypoxia. TGF-b1 inhibition promoted
genomic stability and prevented a senescent phenotype.
Materials and Methods
Fetal Hearts
LV and right ventricle (RV) paired myocardial samples were
obtained from 32 second-trimester fetuses with HLHS
(median gestational age, 23 weeks; range, 20e27 weeks): 18
with moderate HLHS (ie, mitral and aortic valve stenosis and
moderate LV and aortic hypoplasia) and 18 with severe HLHS
(ie, mitral and aortic valve atresia and severe LV and aortic
hypoplasia). We also studied 17 gestational ageematched
control fetuses with no heart disease (median gestational age,
22 weeks; range, 19e27 weeks) (P Z 0.38 versus HLHS).
Samples from the LV and RV free wall were acquired from the
pathology department at the time of fetal autopsies performed
as soon as possible after pregnancy termination or fetal demise.
Samples were processed for studies as described below.
Results were compared between normal and HLHS hearts and
LV and RV paired samples. All investigations were conducted
according to the Declaration of Helsinki principles. Studies
were approved by the Hospital for Sick Children and the
Mount Sinai Hospital institutional review boards, and written
informed consent was obtained from study participants
(pregnant mothers) before inclusion in the study.
Immunohistochemistry
Myocardial tissues were sectioned (5 mm), deparafﬁnized,
rehydrated, and heated in a steamed water bath with an
epitope retrieval solution (Dako, Glostrup, Denmark).
Cultured cells were ﬁxed with 4% paraformaldehyde. Tissue
sections (and ﬁxed cells) were incubated overnight at 4CThe American Journal of Pathology - ajp.amjpathol.orgusing the following primary antibodies: i) growth factors:
hypoxia-inducible factor (HIF)-1a, vascular endothelial
growth factor (VEGF) (Abcam, Cambridge, MA), and
antiethymosin b4 (TB4) (Santa Cruz Biotechnology Inc,
Santa Cruz, CA); ii) DNA damageerelated gH2AX
(Berthyl, Montgomery, TX), anti-p53 binding protein 1
(53BP1) (Abcam), and anti-p53 (phospho S6) (Abcam); iii)
cell cycle progression markers: antiecyclin-dependent
kinase (CDK4) (Santa Cruz Biotechnology) and antieKi-67
(Chemicon, Billerica, MA); iv) differentiated cardiac
markers: antisarcomeric myosin, MF20 (MAbTrapGII;
Pharmacia, Uppsala, Sweden), a-smooth muscle actin
(SMA) (Abcam), cardiac troponin T (cTnT) (Abcam), and
CD31 (Dako); v) capillary density: antievon Willebrand
factor (vWF) (Abcam); and vi) ﬁbrosis-related double
staining for antiea-SMA (Abcam) and ﬁbroblast-speciﬁc
protein (FSP1) (Abcam), TGFB1 (Abcam), E-cadherin
and transcription factor 21 (TCF21) (LSBio, Seattle, WA).
Sections were visualized with anti-mouse, anti-rabbit, or
anti-goat IgG antibodies conjugated with tetramethylrho-
damineisothiocyanate and ﬂuorescein isothiocyanate
(Sigma-Aldrich, St. Louis, MO). Slides were mounted with
Vectashield mounting medium with DAPI (Vector, Burlin-
game, CA) and examined on Zeiss LSM510 META
confocal microscope or Nikon ECLIPSE E1000 microscope
and analyzed with Volocity software, version 5.0 (Perkin-
Elmer Inc, Waltham, MA), or Open Lab software version 3
(PerkinElmer Inc). Also, for immunoperoxidase staining,
Envision Doublestain System (Dako) was used, and the
reaction was visualized by the enzyme substrate dia-
minobenzidine. Permanent red chromogen visualized the
second reaction. Sections were counterstained with Mayer’s
hematoxylin (Dako) or nuclear fast red (TACS assay kits,
Trevigen, Gaithersburg, MD) and examined using light
microscopy (Leica, Wetzlar GmbH, Bannockburn, ON,
Canada). Fibrosis-associated collagen blue expression was
evaluated using Masson’s trichrome staining.
Myocyte number, capillary number, and cardiac progen-
itor lineages were counted using a GSA Image Analyzer
(GSA Bansemer & Scheel GbR, Rostock, Germany) to
identify marker-positive cells with application of common
threshold value and inversion of digital images and
expressed as a percentage of the total cells. A similar
approach was used to quantify cells positive for DNA
damage markers and cell cycle progression markers.
Capillary density was expressed as a ratio of capillary to
myocyte numbers per section. Ten sections (10 ﬁelds per
section) at 400 magniﬁcation in each staining were used to
calculate the mean density per high-power ﬁeld. Only ﬁelds
in the cross section were selected for capillary density
quantiﬁcation. Capillary density was compared between
fetuses 22 weeks of gestational age and those >22 weeks
of gestational age. Double immunostaining of gH2AX
with cTnT, CD31, and a-SMA was performed to identify
which lineages had greater DNA damage. The number of
SMAþ/FSP1þ double-positive cells was also measured.721





HIF1A Forward: 50-GACAAGCCACCTGAGGAGAG-30 245
Reverse: 50-GAAAGGCAAGTCCAGAGGTG-30
VEGF Forward: 50-GAGCCTTGCCTTGCTGCTCTAC-30 148
Reverse: 50-CACCAGGGTCTCGATTGGATG-30
TB4 Forward: 50-CAGACCAGACTTCGCTCGTA-30 137
Reverse: 50-GCTTCTCCTGTTCAATCGT-30
TGFB1 Forward: 50-GCACGTGGAGCTGTACCA-30 152
Reverse: 50-CAGCCGGTTGCTGAGGTA-30
p53 Forward: 50-GTTCCGAGAGCTGAATGAGG-30 159
Reverse: 50-TCTGAGTCAGGCCCTTCTGT-30
p16 Forward: 50-AAGGTCCCTCAGACATCCC-30 90
Reverse: 50-TGTAGGACCTTCGGTGACTG-30
p18 Forward: 50-CGATTTGAAAGACCGAACTG-30 129
Reverse: 50-GGCAGGTTCCCTTCATTATC-30
GAPDH Forward: 50-GCTGAGAACGGGAAGCTTGT-30 136
Reverse: 50-TCTCCATGGTGGTGAAGACG-30
Gaber et alQuantiﬁcation of signal intensity and density was performed
on the Cellomics Arrayscan VTI-HCS Reader (Thermo
Scientiﬁc, Ottawa, ON, Canada), which provides high-
content cellular imaging, and analyzed by Targeted Acti-
vation BioApplication (Thermo Scientiﬁc). Comparisons
were made between LV from control hearts and LVs from
moderate and severe fetal HLHS samples and between LV
and RV from severe fetal HLHS samples.
b-Galactosidase (b-gal) activity was detected using
senescence-galactosidase staining kit (Cell Signaling, Dan-
vers, MA). Frozen myocardial sections were embedded and
cryosectioned (5 mm). Slides were incubated with b-gal
staining solution for 24 hours at 37C. Sections were stained
with nuclear fast red (TACS) and captured under a Leica
DM LB2 microscope for development of blue color, and
signal intensity was analyzed with Open Lab software.
Apoptosis was detected with the CardioTACS In situ
Apoptosis Detection Kit (R&D System, Minneapolis, MN),
In Situ Cell Death Detection Kit, Fluorescein (Roche,
Mannheim, Germany) TUNEL staining method as per
manufacturer instructions. Fixed cells were incubated with
TUNEL reaction mixture, and negative and positive controls
were incubated with labeling solution and DNase I solution,
respectively, and counterstained with Vectashield mounting
medium with propidium iodide (Vector). The stained
samples were examined using a Nikon SCLIPSE E1000 and
LSM 510 Meta Confocal microscopes and analyzed with
Open Lab and Volocity version 5.02 software.
TRF Assay
Telomere lengths were determined by a terminal restriction
fragment (TRF) kit (Roche Diagnostics, Quebec City, QC,
Canada). Brieﬂy, 1 to 2 mg of extracted genomic DNA
samples were digested with RsaI and HinfI at 37C for 2
hours and run on 0.8% agarose gels at 12 mAmp for 12
hours. DIG molecular weight marker was loaded on both
sides of the samples. After denaturation and neutralization
of the gel, digested DNA samples were transferred to
Hybond-Nþ membrane (GE Healthcare Biosciences, Pitts-
burgh, PA) overnight with 10 standard saline citrate
buffer. The blot was then hybridized to telomere-speciﬁc
digoxigenin-labeled probe for 3 hours at 42C and washed
with washing buffer. Chemiluminescent detection of
hybridized telomeres was performed, and the mean TRF
length was calculated according to manufacturer protocol
and formula and reported as telomere lengths.
Real-Time PCR for Myocardial mRNA Expression
Total RNA was isolated using the RNeasy Fibrous Tissue
Midi Kit (Qiagen, Valencia, CA) from frozen myocardial
samples. Quality and integrity of total RNA were assessed
on 1% formaldehyde-agarose gels. The target genes, primer
sequences, and PCR amplicon size are outlined in Table 1.
Relative mRNA expression of the following genes were722measured using real-time PCR: growth factors and related
genes: HIF1A, VEGF, TB4, and TGFB1; and tumor
suppressors or oncogenes: p53, p16, and p18. GAPDH was
used as the housekeeping gene to correct for differences in
transcriptional regulation across samples. Brilliant II SYBR
Green Q-PCR Master Mix (Stratagene, Cedar Creek, TX)
was used for transcription and ampliﬁcation using the ABI
PRISM 7000 Thermocycler (AB Applied Biosystems,
Valencia, CA). Real-time quantitation was performed using
the iCycler iQ system (BioRad, Hercules, CA).
hPSCs
hPSC studies were approved by the Stem Cell Oversight
Committee of Canada. HES2 cell lines from the National
Stem Cell Bank (WiCells, Madison, WI) were differentiated
into cardiac lineages using a published cardiac differentiation
protocol (courtesy of Gordon Keller, McEwen Centre for
Regenerative Medicine, Toronto, ON, Canada).4 Cells at day
17 of cardiac differentiation stage were passaged from
suspension culture of embryoid bodies (EBs) to monolayer
culture or studied as EBs. Cells were cultured in StemPro
medium (Invitrogen, Carlsbad, CA) supplemented with 5 ng/
mL of human bFGF and with 10 ng/mL of human VEGF
during differentiation and without VEGF during hypoxia
exposure. All factors were purchased from R&D Systems.
Cultures were maintained in a 5% CO2/air environment. EBs
or monolayer cultured cells that reached 50% to 60%
conﬂuence were exposed to hypoxia (1% O2, 5% CO2, and
75% N2) in a hypoxia chamber (Billups-Rothenberg Inc, Del
Mar, CA) without supplementation of VEGF and FGF
StemPro media for 72 hours. Cells were studied using im-
munostaining, real-time PCR, electron microscopy, and ﬂow
cytometry, and results were compared between normoxic
and control cells (5% CO2/air environment), cells subjected
to 1% O2 for 72 hours, and cells treated with 10 mmol/L of
SB431542, a TGF-b1 inhibitor (Tocris, Monrovia, CA)ajp.amjpathol.org - The American Journal of Pathology
Senescence in Fetal HLHSduring hypoxia exposure. For assessment, cells were ﬁxed to
measure immunoﬂuorescence staining for markers
(described earlier) and population doubling time. Real-time
PCR for custom array was performed as described earlier.
Brieﬂy, total RNA was isolated using the RNeasy Fibrous
Tissue Mini Kit (Qiagen) from frozen cells. A RT Proﬁler
PCR custom array was designed (catalog no. CAPH-11134C;
Qiagen) that included genes involved in pathways of cellular
senescence, including the p53 pathway (TP53BP2, PTEN,
MAPK14, HRAS), oxidative stress (SOD2, PRKCD), proﬁ-
brotic (SNAIL), antiﬁbrotic (BMP7, TAGLN), smooth muscle
(CNN1), extracellular matrix (ECM) (COL1A2, COL3A1,
COL1A1, ELN), ECM turnover enzymes (MMP2, MMP9,
TIMP1), TGF superfamily (BMP7, TGFB1, SMAD2),
epithelial-mesenchymal transition (AKT1, ILK, SMAD2,
SNAIL, TGFB1), cell adhesion (CD44), and transcription
factors (SRF, mTOR). RT2 Real-Timer SyBR Green PCR
Mix was purchased from Qiagen. PCR was performed on
7700 ABI Prism 7700 sequence detector (AB Applied
Biosciences). Data analysis was performed using the DDCT
method.
Double immunostaining of ph-P53 (Ser6) with cTnT,
CD31, and a-SMA was performed to identify which line-
ages had DNA damage. Telomere lengths were determined
by a TRF kit (Roche Diagnostics). hTERT (AB Applied
Biosystems) was measured by quantitative real-time PCR
(qPCR) (described earlier). Beating rate was counted under
inverted microscope as beats per minute in control, hypoxia,
and hypoxia plus TGF-b1 inhibitor, SB431542-treated EBs.
Videos of beating EBs were taken using Handycam
Camcorder (Sony, Toronto, ON, Canada).
Flow Cytometry
Differentiation stage day 20 EBs were dissociated to single
cells after 72-hour normoxia, hypoxia, and hypoxia plus
SB431542 incubation. Cells were then treated with primary
antibodies, including rabbit polyclonal anti-CD31 (Abcam),
mouse monoclonal anti-cTnT, CD31, a-SMA, S100A/FSP1,
and gH2AX (phospho S139) (Abcam) for 40 minutes at 4C,
followedby30-minute 37C incubationwith allophycocyanin-
labeled anti-mouse and anti-rabbit secondary antibodies (BD
Pharmingen, San Jose, CA) and phycoerythrin-conjugated
cTnT, signal-regulatory protein a (SIRPA/CD172A), CD31,
and platelet-derived growth factor receptor (PDGFR)-b (BD
Pharmingen). Cells were also stained with ﬂuorescein iso-
thiocyanate, phycoerythrin, and allophycocyanin-labeled iso-
type-matched immunoglobulins (BD Pharmingen) and used as
negative controls. Bromodeoxyuridine (BrdU) was added to
growingEBs and incubated overnight. EBswere harvested and
dissociated to single cells, ﬁxed with 70% ethanol, and stained
with a BrdU-labeled allophycocyanin BrdU Flow Kit (BD
Pharmingen) for quantiﬁcation of proliferating cells. For DNA
content quantiﬁcation of cell cycle check points, the cells were
harvested, ﬁxed with ethanol, and stained with propidium
iodide in the presence of RNase. The cells were analyzed withThe American Journal of Pathology - ajp.amjpathol.orgthe BDLSR II Flow Cytometer System and FlowJo software
version 10.0.6 (BD Biosciences, San Jose, CA).
Endothelial and Smooth Muscle Lineages
Human umbilical vein endothelial cells (HUVECs) (Life-
line, Cell Technology, Frederick, MD) were cultured in
VascularLife EnGS Endothelial Cell Culture Medium
(Lifeline, Cell Technology) together with all of the
components provided in the Low Serum Growth Supple-
ment kit and the VascuLife EnGS LifeFactors kit (Lifeline,
Cell Technology). Seventy-two-hour normoxia, hypoxia,
and hypoxia plus SB431542 incubated HUVECs were used
for ﬂow cytometry to quantify DNA content and cell cycle
analysis. SMC-enriched populations were derived from
hPSC differentiation using a previously published SMC
differentiation protocol that yields approximately 70% pure
SMCs.6 For matrigel assay, 200 mL of undiluted matrigel
(BD Gmbh, Heidelberg, Germany) was placed on 24-well
plates and incubated for 1 hour at 37C. Then 5  104
HUVECs were reconstituted in 500 mL of culture medium
and plated on the BD matrigel layer. Capillary tube
formation was observed by converted microscope after
incubation for an additional 24 hours at 37C. Scores were
given from 0 for individual cells separated to 5 for devel-
opment of complex mesh-like structures.7
Statistical Analysis
All results were expressed as means  SD. Analysis was
performed to measure differences between LV from control,
moderate HLHS, and severe HLHS fetal hearts; paired
LV and RV samples from severe HLHS; and cardiac
lineages treated with normoxic, hypoxic, and hypoxia plus
SB431542. The following variables were analyzed: number
of cells with evidence of DNA damage, number of sen-
escent cells, telomere length, cell proliferation index, myo-
cyte density, capillary density, population doubling time,
mRNA expression of cell cycling and growth factor genes,
semiquantitative comparison by intensity of immunostain-
ing, and ﬂow cytometric quantitation of cardiac progenitors
and differentiated lineages. Continuous variables were
compared between HLHS and control samples using one-
way analysis of variance and the nonparametric U-test.
Differences were considered statistically signiﬁcant at P <
0.05. Data were statistically evaluated using StatView
software, version 5.0 (SAS Institute Inc, Cary, NC).
Results
LV Phenotype in Fetal HLHS Samples
We found strong nuclear localization of HIF-1a, the master
regulator of the hypoxia response, in the LV in HLHS samples
compared with control hearts using immunoﬂuorescence
(Figure 1A). Downstream angiogenic factors, VEGF, and TB4723
Figure 1 HIF-1a and downstream growth factor expression in fetal HLHS. A: Immunostaining of the LV (representative images) revealed strong nuclear
expression of HIF-1a (red) and reduced expression of VEGF (red) and TB4 (green) in severe fetal HLHS hearts compared with controls. DAPI (blue) represents
nuclear staining. B: mRNA expression of HIF-1a is higher in severe fetal HLHS hearts compared with moderate HLHS hearts and controls. VEGF and TB4 mRNA
expression is lower in moderate (dark gray) and severe (light gray) HLHS hearts compared with controls (black). Also, VEGF and TB4 mRNA expression is lower
in severe compared with moderate HLHS hearts. *P < 0.05 versus controls; yP < 0.01 versus controls; zP < 0.05 versus moderate HLHS hearts (nZ 10 in each
group). Mod, moderate; Sev, severe. Original magniﬁcation: 600 (HIF-1a), 200 (VEGF) and 400 (TB4) (A).
Gaber et alwere down-regulated on immunostaining (Figure 1A) and
mRNA expression (Figure 1B). These differences were more
marked in severe compared with moderate HLHS samples.
Both VEGF and TB4 are important for cardiac progenitor
recruitment, differentiation, and vasculogenesis.8
DNA Damage and Senescence
We assessed cell survival in the context of impaired growth
factors by studying the DNA damage response. HLHS hearts
had multiple green nuclear foci of gH2AX, a phosphorylated
histone that binds to sites of double-stranded DNA breaks
(Figure 2A). There were more gH2AX-positive cells in
moderate (16%  4%) and severe HLHS samples (36% 
6%) compared with controls (1  1%) (P < 0.01 versus
controls). Damaged cells had up-regulation of nuclear
phospho-p53 (serine6), a tumor suppressor that induces cell
cycle arrest to allowDNA repair to occur (Figure 2A). Failure
of adequate DNA repair results either in apoptosis or senes-
cence where the cell permanently exits the cell cycle and
stops replicating. We found increased expression of the
senescence marker b-gal (Figure 2A) but no apoptosis on
TUNEL staining in the injured cells (Supplemental
Figure S1A). Senescence was further conﬁrmed through
electron microscopy, which revealed nuclear heterochro-
matin foci in HLHS samples compared with compact nuclear
chromatin in control LVs (Supplemental Figure S1B). These
foci, called senescence-associated heterochromatin foci,
represent a morphologic marker of cellular senescence.9724Cell Cycle Arrest
Senescence permits cell survival at the cost of cell replica-
tion, which can be seen through induction of cell cycle
arrest in damaged cells. Cell cycle arrest in HLHS was
evident by the decrease in the nuclear proliferation antigen
Ki-67 and cyclin-dependent kinase CDK4 (G1-phase cell
cycle progression activator) expression (P < 0.01 versus
controls) (Figure 2, A and B). The up-regulation of the
oncogene p53 and of the G1 cell cycle inhibitors p16 and
p18 in HLHS (P < 0.05 versus controls) suggests that the
cell cycle arrest and senescence was potentially mediated by
oncogenes (Figure 2C). There was no telomere shortening
in the LV of HLHS compared with the RV from the same
hearts (Supplemental Figure S1, C and D), indicating that
the senescence was stress induced as opposed to replicative
senescence, which is associated with telomere shortening.
We conclude that chronic hypoxia in fetal HLHS may be
a factor in the observed severe DNA damage and cell
senescence, resulting in reduced growth factor release in the
microenvironment.
Endothelial Susceptibility to Genotoxic Injury
To determine which cell types were most susceptible to
DNA damage, we performed double staining with gH2AX-
and cardiac lineageespeciﬁc markers (ie, cTnT for car-
diomyocytes, CD31 for endothelial cells (ECs), and SMA
for SMCs). There were 90%  4% gH2AXþ ECs, 56% ajp.amjpathol.org - The American Journal of Pathology
Figure 2 DNA damage, premature senescence,
and oncogene up-regulation in fetal HLHS. A:
Immunostaining of the LV (representative images)
revealed more gH2AX-positive cells (green foci),
higher phospho-P53 (ser6) expression (green),
and higher senescence-associated b-gal expression
(blue) in moderate and severe HLHS hearts
compared with controls. Ki-67epositive (red,
nuclear) and CDK4-positive (green, nuclear) cells
are lower in moderate and severe HLHS hearts
compared with controls. DAPI (blue) represents
nuclear staining. B: Cell counting revealed a lower
number of Ki-67epositive and CDK4-positive cells
in moderate (dark gray bars) and severe fetal HLHS
hearts (light gray bars) compared with controls
(black bars). C: Real-time PCR revealed higher
mRNA expression of the tumor suppressor onco-
genes p53, p16, and p18 in moderate (dark gray
bars) and severe HLHS hearts (light gray bars)
compared with controls (black bars). *P < 0.05
versus controls; yP < 0.01 versus controls (nZ 10
in each group). Mod, moderate; Sev, severe.
Original magniﬁcation: 1000 (gH2AX); 400
(phospho-P53); 600 (Ki-67 and CDK4) (A).
Senescence in Fetal HLHS2% gH2AXþ cardiomyocytes, and 18%  3% gH2AXþ
SMCs in HLHS hearts versus 2%  1% gH2AXþ cells in
controls (P < 0.01 versus controls) (Figure 3, A and B),
indicating greatest susceptibility of ECs to genotoxic injury
compared with other cardiac cell types.
Reduced Cardiac Progenitors and Differentiated
Lineages
Not surprisingly, DNA damage was associated with
reduced population of progenitor and differentiated
cardiac lineages. Speciﬁcally, we found fewer Nkx2.5þ
cardiac progenitors, and CD34þ endothelial progenitors
(Figure 4A) and reduced mRNA expression of progenitor
markers (P < 0.05 versus controls) (Figure 4B). The
population of differentiated lineages (ie, MF20þ car-
diomyocytes and vWFþ ECs) was also lower in HLHSThe American Journal of Pathology - ajp.amjpathol.orgsamples versus controls. Interestingly, we found a higher
proportion of SMAþ cells in severe HLHS hearts
compared with control hearts (representative images are
given in Figure 4A). Quantiﬁcation by immunoﬂuores-
cence conﬁrmed lower myocyte and capillary numbers and
lower capillary density in HLHS samples compared with
controls (Figure 4C). In addition, capillary density was
lower in advanced gestation HLHS fetuses (>22 weeks)
compared to those 22 weeks of gestational age. This was
seen in both moderate and severe HLHS hearts
(Figure 4D). In contrast, SMAþ cells increased from 10%
in control hearts to approximately 70% in HLHS hearts (P
< 0.01 versus controls) (Figure 4E). We conclude that fetal
HLHS was associated with depletion of cardiac progenitors
and differentiated endothelial and myocyte lineages but
with an increase in SMA-expressing cells and that the
phenotype progressed with advancing gestation.725
Figure 3 DNA damage in cardiac lineages in fetal HLHS. A: Double
staining of the LV (representative images) for gH2AX (green, nuclear) and
cardiac lineageespeciﬁc markers cTnT (red), CD31 (red), and SMA (red)
revealed DNA damage in all three lineages in severe HLHS hearts compared
with controls. DAPI (blue) represents nuclear staining. B: Quantiﬁcation
revealed a higher number of gH2AXþ myocytes, ECs, and SMCs in fetal HLHS
hearts (gray bars) compared with controls (black bars), with ECs being the
most affected lineage. *P < 0.01 versus controls; yP < 0.05 versus SMAþ
cells. zP < 0.05 versus cTnTþ cells (n Z 10 in each group). Sev, severe.
Gaber et alIncreased Fibroblast Transformation
To determine the nature of SMAþ cells, we performed co-
immunostaining with SMA and FSP1. FSP1 is expressed
in mature ﬁbroblasts and immature cells transitioning to
mesenchymal lineages.10 Trichrome staining revealed
extensive perivascular and interstitial ﬁbrosis in HLHS
hearts with an abundance of FSP1þ cells compared with
controls (Figure 5, A and B). Co-immunostaining revealed
a high proportion of SMAþ/FSP1þ cells suggestive of
proliferating myoﬁbroblasts in areas of interstitial ﬁbrosis in
HLHS hearts (50%  2% in HLHS samples versus 2% 
2% in controls, P < 0.01) (Figure 5, C and D). Importantly,
the ﬁbrosis was not driven by epithelial or endothelial-
mesenchymal transition because E-cadherin, an epicardial
marker, and TCF21/POD1, an epithelial-mesenchymal
transition marker, expression was seen primarily in the
epicardium and not the myocardium of both control and726HLHS hearts (Supplemental Figure S2). We did however
ﬁnd co-localization of the proﬁbrotic cytokine TGFB1 with
FSP1 in HLHS hearts (Figure 5C) and TGF-b1 mRNA up-
regulation by qPCR (P < 0.01 versus controls) (Figure 5E).
This may suggest a role for TGF-b1 in myoﬁbroblast
proliferation and ﬁbrosis.
LV versus RV Phenotype in HLHS
To exclude a generalized effect of intrauterine stress in
HLHS, we studied paired LV and RV samples from the
same hearts (10 fetal HLHS hearts and 10 control hearts).
Up-regulation of DNA damage and senescence markers
(gH2AX, phospho-p53, senescence-associated b-gal, and
nuclear heterochromatin foci), and down-regulation of Ki-
67 and CDK4 were restricted to the LV in HLHS hearts
(Supplemental Figure S3, A and B). mRNA expression of
the oncogenes p53, p16, and p18 was higher and capillary
density was lower in the LV versus RV (Supplemental
Figure S3, C and D). We conclude that the injury in
HLHS is restricted to the LV, which may suggest
a combination of genetic susceptibility and regional
microenvironmental perturbations. Although the ﬁndings
in human hearts are observational, together they raise the
possibility that TGF-b1 up-regulation, DNA damage, and
premature senescence contribute to the phenotype of
ﬁbrosis, reduced angiogenesis, and LV growth failure in
HLHS.
Effect of Hypoxia in hPSC-Derived Cardiac Lineages
To examine the role of hypoxia and TGF-b1 up-
regulation in mediating injury, we subjected hPSCs
during cardiac differentiation to chronic hypoxia and
assessed the ability of TGF-b1 inhibition to prevent
injury. In brief, human embryonic HES2 cell lines were
differentiated into cardiac lineages using an established
cardiac differentiation protocol.4 This protocol yields
40% to 60% myocytes and 20% to 30% each of ECs and
SMCs. To determine the degree of hypoxia that would
reproduce the damaging effects seen in fetal hearts, we
exposed hPSC-derived cardiac lineages to varying dura-
tion and severity of hypoxia. There was a dose-dependent
response to hypoxia with an increase in gH2AXþ cells
from 0.02% in controls, 8% with 5% O2 per 24 hours,
11% with 1% O2 per 24 hours, 16% with 1% O2 per 48
hours, and 26% with 1% O2 per 72 hours. All further
experiments with hypoxia were performed in 1% O2 for
72 hours, and comparisons were made between normoxic
or control cells, hypoxic cells, and hypoxic cells treated
with TGF-b1 inhibitor.
DNA Damage and Senescence
Similar to fetal HLHS, hypoxia-treated cells had up-
regulation of HIF-1a but not of the angiogenic growthajp.amjpathol.org - The American Journal of Pathology
Figure 4 Reduced cardiac progenitors, myo-
cytes, and ECs in fetal HLHS. A: Immunostaining of
the LV (representative images) revealed reduced
cardiac progenitor marker Nkx2.5 (red nuclear
staining) and endothelial progenitor marker CD34
(red); reduced differentiated lineage markers,
sarcomeric myosin, MF20 (myocyte marker)
(green), and vWF (endothelial marker) (red); and
higher SMA expression in HLHS hearts compared
with controls. DAPI (blue) represents nuclear
staining. B: qPCR revealed lower Nkx2.5 and CD34
mRNA expression in severe HLHS hearts (gray)
compared with controls (black). C: Myocyte
number (ie, MF20þ cells) and capillary number (ie,
vWFþ cells) are lower in moderate and severe HLHS
hearts versus controls. D: Capillary density (ie,
ratio of capillaries to myocytes) is lower in severe
HLHS hearts compared with controls. In severe
HLHS, capillary density is lower in older gestation
fetuses (>22 weeks) compared with earlier
gestation fetuses (22 weeks). E: SMAþ cells are
higher in HLHS hearts compared with controls. *P
< 0.01 versus controls; yP < 0.05 versus earlier
gestation (ie, 22 weeks) (nZ 10 in each group).
Mod, moderate; Sev, severe. Original magniﬁca-
tion: 1000 (Nkx2.5); 600 (CD34); 400 (MF20
and vWF) (A).
Senescence in Fetal HLHSfactor VEGF (Figure 6A). qPCR conﬁrmed corresponding
differences at the transcriptional level after hypoxia
(Figure 6B). There was a marked increase in the DNA
damage marker gH2AX and the senescence marker b-gal
(Figure 7A) but no evidence of apoptosis (ie, TUNELþ
cells) (data not shown). The mRNA expression of the tumor
suppressor oncogene p53 and the G1 cell cycle inhibitors
p16 and p18 were also increased in hypoxic cells
(Figure 7B). Therefore, hypoxia exposure induced DNA
damage and senescence in hPSCs, thereby recapitulating the
fetal HLHS phenotype.
Endothelial Susceptibility to Injury
To assess whether ECs were more susceptible to hypoxic
injury, we performed double-staining with cardiac lineage
markers and ph-p53 (Ser6). We found more extensive DNA
damage in ECs with 77% p53þ ECs compared with 55%
p53þ cardiomyocytes and 20% p53þ SMCs (Figure 7, C and
D). We conclude that exposure of immature hPSC-derived
cardiac lineages to hypoxia recapitulates the type of injury
seen in fetal HLHS hearts, with ECs being more susceptible
to injury followed by myocytes and then SMCs.The American Journal of Pathology - ajp.amjpathol.orgTGF-b1 Inhibition Reduces Cell Damage
To assess the role of TGF-b1 in rescuing hypoxia-induced
injury, we treated the cells with 10 mmol/L SB431542,
a TGF-b1 inhibitor, during hypoxia. SB431542 treatment
prevented the up-regulation of the DNA damage marker
53BP1 and of the tumor suppressor ph-p53 (ser6) (Figure 8,
A and B). Hypoxia also decreased proliferating BrdUþ cells
from 21% to 14%; TGF-b1 inhibition prevented this decrease
in proliferation (Figure 8, C and D). The hypoxia-induced
increase in population doubling time (25  3 hours in
controls versus 49  5 hours in hypoxia, P < 0.001) was
similarly prevented by TGF-b1 inhibition (25 5 hours, P<
0.001 versus hypoxia). To determine whether this loss of
replication was related to stress-induced versus replicative
senescence, we measured telomere length and telomerase
expression levels [ie, telomerase reverse transcriptase
(hTERT)], which were not different among controls,
hypoxia-treated cells, and TGF-b1 inhibitoretreated cells
(Figure 8, E and F). As expected, undifferentiated hESCs had
the highest hTERT expression. We conclude that the
decrease in replication potential is related to stress-associated
premature senescence, which is telomerase independent and727
Figure 6 Effect of hypoxia on growth factor expression in hPSC-derived
cardiac lineages. A: Representative images from immunostaining revealed
increased cytoplasmic and nuclear HIF-1a expression (red) and similar VEGF
(green) expression in cells exposed to 1% O2 for 72 hours compared with
controls. B: These differences were also seen in HIF-1a mRNA expression
quantiﬁed by real-time PCR (control, black; hypoxia, gray) (nZ 3 experiments
in each group). *P< 0.05 versus controls. Original magniﬁcation:630 (A).
Figure 5 Myoﬁbroblast proliferation and
ﬁbrosis in fetal HLHS. A: Trichrome staining of the
LV (representative images) revealed increased
perivascular and interstitial collagen (blue) and
disorganized muscle bundles (red) in moderate
and severe HLHS hearts compared with controls.
Immunostaining revealed that FSP1 (green)
expression is higher in moderate and severe HLHS
hearts compared with controls. Blue represents
DAPI nuclear staining. B: FSP1þ cell percentage
(relative to total cell number) is higher in HLHS
hearts compared with controls. C: Double staining
with SMA (red) and FSP1 (green) revealed more
SMAþ/FSP1þ double-positive cells (yellow) in fetal
HLHS hearts compared with controls. This was seen
in areas of both perivascular and interstitial
ﬁbrosis but not in control hearts. There was co-
localization of the proﬁbrotic cytokine TGF-b1
(red) with FSP1 (green) in fetal HLHS hearts but
not in controls. D: Cell counting revealed that the
SMAþ/FSP1þ cell percentage is higher in HLHS
hearts compared with controls. E: qPCR revealed
higher mRNA expression of TGF-b1 in fetal HLHS
hearts compared with controls. *P < 0.01 versus
controls (n Z 10 in each group). Mod, moderate;
Sev, severe. Original magniﬁcation: 50 (peri-
vascular and interstitial collagen); 600 (FSP1)
(A); 600 (C).
Gaber et alpotentially oncogene mediated rather than due to replicative
senescence.11e14
TGF-b1 Inhibition Preserves Myocyte and EC
Populations
We performed ﬂow cytometry to more precisely quantify the
three primary cardiac lineages after exposure to hypoxia and
assess TGF-b1 effects. Flow cytometry revealed a decrease
in cTnTþ and SIRPAþ cardiomyocytes and in CD31þ ECs
with hypoxia compared with normoxic controls (P < 0.05
versus controls). SIRPA is a cell surface marker that was
recently identiﬁed as a robust marker for cardiomyocytes
derived from hPSCs.15 Conversely, we found an increase in
SMAþ and PDGFR-bþ cells with hypoxia. PDGFR-b is
a marker of mature SMCs (Figure 9, A and B). Treatment
with SB431542 prevented the decrease in cardiomyocyte and
EC populations and prevented the increase in SMAþ and
PDGFR-bþ populations (Figure 9, A and B). We conclude
that TGF-b1 inhibition can rescue hypoxia-induced decrease
in cardiovascular lineages.
TGF-b1 Inhibition Reduces Fibroblast Transformation
Similar to fetal HLHS, hypoxia exposure was associated
with a threefold increase in cells co-expressing SMA and
FSP1 (yellow staining) (P < 0.01 versus controls). This
increase was attenuated with TGF-b1 inhibitor treatment
(Figure 9, C and D). qPCR conﬁrmed the threefold increase
in TGF-b1 mRNA in hypoxic cells. (P < 0.01 versus728controls) (Figure 9E). We compared gene expression using
a custom PCR array, with red color representing higher
relative gene expression and green representing lower
relative gene expression. The heat map (Figure 9F)ajp.amjpathol.org - The American Journal of Pathology
Figure 7 Effect of hypoxia on DNA damage and
oncogene up-regulation in hPSC-derived cardiac
lineages. A: DNA damageerelated marker gH2AX
(green nuclear foci) and senescence marker b-gal
(blue) is increased in hypoxic cells. Blue represents
nuclear staining with DAPI. B: qPCR results revealed
higher mRNA expression of the tumor suppressor
oncogene p53 and the G1 cell cycle inhibitors p16
and p18 in hypoxic (gray bars) compared with
control cells (black bars). C: Double immunostaining
revealed co-localization of ph-p53 (green) with
cTnTþ myocytes (red), CD31þ endothelial cells
(red), and SMAþ SMCs (red), indicating DNA damage
in all three lineages. Blue represents nuclear stain-
ing with TO-PRO-3. D: Cellomics quantiﬁcation
conﬁrmed the higher number of ph-p53þ cardiac
lineages in hypoxic cells (gray bars) compared with
controls (black bars), with most severe injury in ECs
followed by myocytes and then SMCs. *P < 0.01
versus controls; yP < 0.05 versus SMAþ cells; zP <
0.05 versus cTnTþ cells (nZ 3 experiments in each
group). Original magniﬁcation: 1000 (gH2AX);
600 (b-gal) (A); 1000 (C).
Senescence in Fetal HLHSdemonstrates hypoxia-induced up-regulation of senescence
genes (TP53BP2, PTEN, MAPK14, HRAS), oxidative stress
genes (SOD2, PRKCD), proﬁbrotic genes (SNAIL), smooth
muscle gene (CNN1), ECM genes (COL3A1, COL1A1,
ELN) (except for COL1A2, which was reduced), remodeling
enzyme genes (MMP2, MMP9, TIMP1), TGF superfamily
genes (TGFB1, SMAD2), epithelial-mesenchymal transition
genes (AKT1, ILK, SMAD2, SNAIL, TGFB1), cell adhesion
gene (CD44), and transcription factors (SRF, mTOR). There
was a down-regulation of antiﬁbrotic genes (BMP7,
TAGLN ). Importantly, changes in gene expression seen
with hypoxia were reversed with TGF-b1 inhibition
(Figure 9F). We conclude that a hypoxia-induced increase in
cellular and oxidative injury and ﬁbroblast transformation
during cardiac differentiation can be prevented by TGF-b1
inhibition.
TGF-b1 Inhibition Improves EB Contractility
To assess the functional effect of these changes, we assessed
EB contractility by live imaging of beating EBs
(Supplemental Videos S1, S2, and S3). EBs subjected to
hypoxia had a marked decrease in beating rate from 64  14
beats/min to 38  7 beats/min with hypoxia (P < 0.01The American Journal of Pathology - ajp.amjpathol.orgversus controls). This was prevented by treatment with
TGF-b1 inhibitor (51  1 beats/min, P < 0.05 versus
hypoxia). Overall, our ﬁndings conﬁrm that chronic hypoxia
can induce an in vitro cellular phenotype in hPSC-derived
cardiac lineages that mimics the phenotype of fetal HLHS
and that can be rescued by TGF-b1 inhibition.
Effect of Hypoxia on ECs and SMCs
To further assess lineage-speciﬁc susceptibility to hypoxia,
we studied pure EC populations using HUVECs and SMC-
enriched populations derived from hPSC differentiation.6
Hypoxia increased the G1/S phase of cell cycle arrest
from 75% in controls to 86% with hypoxia in HUVECs
(Figure 10, A and C). This increase was not seen in cells
treated with a TGF-b1 inhibitor (P < 0.05 versus controls)
(Figure 10, B and C). Hypoxia caused a smaller nonsig-
niﬁcant increase in G1/S cell cycle arrest in the SMC-
enriched population derived from hPSCs compared with
HUVECs (Figure 10, B and C). To assess the functional
consequences of endothelial injury, we measured capillary
tube formation by HUVECs in 3-dimensional matrigel
assays and assigned scores from 0 for individual separated
cells to 5 for development of complex mesh-like structures.7729
Figure 8 Effect of TGF-b1 inhibition on
hypoxia-induced DNA damage, oncogene up-
regulation, cell proliferation, and telomere length
in hPSC-derived cardiac lineages. A: Immuno-
staining revealed higher expression of 53BP1
(green, nuclear foci) and phospho-p53 (green,
nuclear foci) in hypoxic versus control cells. Blue
represents nuclear staining with DAPI. Treatment
with the TGF-b1 inhibitor SB431542 prevented
hypoxia-induced increase in DNA damage markers.
B: Cellomics quantiﬁcation conﬁrmed these
differences among the control (black bar), hypoxia
(gray bar), and TGF-b1 inhibitor groups (light gray
bar). C and D: Flow cytometry (representative
plots) revealed reduced population of BrdU-
positive (ie, proliferating cells with hypoxia);
this decrease was prevented by TGF-b1 inhibition.
E and F: Southern blot TRF analysis of telomere
lengths and qPCR analysis of telomerase levels
revealed lower hTERT expression in differentiated
compared with undifferentiated hPSCs. There is no
difference among normoxia, hypoxia, and TGF-b1
inhibitoretreated hPSCs, indicating that the
senescence was telomere independent. *P < 0.05
versus control (nZ 3 experiments in each group).
Hyp; hypoxia; Inh, TGF-b1inhibitor; TL, telomere
length; NC, normoxic control; hESC human
embryonic stem cell.
Gaber et alTube forming capacity in vitro was markedly reduced with
hypoxia compared with controls (P < 0.01 versus controls)
but was preserved with TGF-b1 inhibitor treatment
(Figure 10, D and E). We conclude that ECs have a higher
susceptibility to chronic hypoxia that causes endothelial
senescence and cell cycle arrest and reduces tube forming
capacity, whereas SMCs demonstrate a higher tolerance to
chronic hypoxia.
Discussion
HLHS is a complex congenital heart malformation that is
lethal without surgery. Survival requires multiple operations
in the ﬁrst 2 to 3 years of life to restore a physiologic
circulation. This is associated not only with high mortality
and morbidity but also with ventricular dysfunction and
premature heart failure. Fetal interventions to restore LV
ﬂow are often unsuccessful or result in severe LV diastolic
dysfunction that limits survival. Endocardial ﬁbroelastosis is
an important risk factor for poor outcomes after surgical
repair of HLHS. The mechanism of this ﬁbrosis and poor
ventricular growth and function has been poorly understood.
We hypothesized that although the underlying cause of
HLHS may be genetic, the progressive abnormalities in LV
growth and LV ﬁbrosis during fetal life may be exacerbated
by oxygenation and ﬂow abnormalities.
Overall, our study suggests that the fetal LV in HLHS
undergoes reprogramming with decrease in cardiac lineages730and increase in ﬁbroblast lineages possibly in an attempt to
survive in a hostile environment at the cost of decrease in
endothelial andmyocyte lineages. The process involves TGF-
b1 up-regulation, DNA damage, premature cell senescence,
and loss of replication. The reduction in cardiac progenitors
and differentiated myocytes and ECs and the increase in
myoﬁbroblasts likely promote tissue ﬁbrosis, further
affecting chamber growth and function. The recapitulation of
these ﬁndings in hPSC-derived cardiac lineages exposed to
hypoxia and prevention by TGF-b1 inhibition suggests an
important role for hypoxia-induced TGF-b1 activation in
mediating this injury. In particular, endothelial susceptibility
to injury and senescence implicates impaired vasculogenesis
as a key contributor to the observed phenotype.
The ﬁrst important ﬁnding of our study was that of stress-
or oncogene-associated senescence in malformed human
fetal hearts, which has not been previously reported.
Senescence occurs if genotoxic injury is too severe to permit
adequate DNA repair and restore cellular integrity.16,17
Senescent cells, although functional, lack replicative
capacity and fail to produce growth factors necessary to
support organ growth. There was evidence of extensive cell
senescence in fetal HLHS. The failure of senescent cells to
produce VEGF and TB4 despite up-regulation of HIF-1a
may have contributed to an adverse microenvironment that
lacks the ability to support the survival, replication, and
differentiation of cardiac progenitors, in particular ECs that
are more susceptible to injury. Although an assessment ofajp.amjpathol.org - The American Journal of Pathology
Figure 9 Effect of TGF-b1 inhibition on cardiac differentiation and myoﬁbroblast proliferation in hPSCs. A and B: Quantiﬁcation by ﬂow cytometry revealed
a reduction in cTnTþmyocytes, SIRPAþmyocytes, and CD31þ ECs but an increase in SMAþ and PDGFR-bþ cells after hypoxia. This was prevented in cells treatedwith
the TGF-b1 inhibitor SB431542 [representative ﬂow plots (A) and cellomics quantiﬁcation (B) shown]. Black bars, control; light gray bars, hypoxia; dark gray bars,
hypoxia plus TGF-b1 inhibitor. C: Immunostaining (representative images) revealed co-localization (yellow) of SMA (red) and FSP1 (green), indicating increase in
myoﬁbroblasts in hypoxia-treated cells. TGF-b1 (brown) expression is also increased in hypoxic cells. This was not seen in normoxic controls or in TGF-b1 inhibitor,
SB431542-treated cells, indicating a role for TGF-b1emediated myoﬁbroblast transformation. D: High content imaging conﬁrmed the higher number of SMAþ/
FSP1þ double-positive cells with hypoxia but not with hypoxia plus TGF-b1 inhibition. E: qPCR revealed increased mRNA expression of TGF-b1 in hypoxia-treated
cells but not in hypoxia plus TGF-b1 inhibitoretreated cells. F: Heat map showing gene expression in control, hypoxia, and hypoxia and TGFB1 inhibitoretreated
cells. Hypoxia induced an up-regulation in senescence genes, oncogenes, and proﬁbrotic genes compared with controls. This was prevented by TGF-b1 inhibitor
treatment. Red indicates up-regulation of gene expression relative to controls and green indicates down-regulation of gene expression. *P< 0.05 versus controls
(nZ 3 experiments in each group). Hyp, Hypoxia; Inh, TGF-b1 inhibitor. Original magniﬁcation: 600 (C).
Senescence in Fetal HLHSthe long-term effect of this reprogramming was beyond the
scope of our study, severe and irreversible loss of replication
potential during this critical fetal growth period is likely to
signiﬁcantly impair LV growth in the short term and LV
function and regenerative capacity in the long term and may
explain the failure of fetal intervention strategies to reverse
injury and promote chamber growth.
The second important ﬁnding was the role of TGF-b1 in
this phenotype. Damaged cells produce proﬁbrotic cyto-
kines such as TGF-b1, which in turn promote myoﬁbroblast
transformation of either endogenous ﬁbroblasts or non-
ﬁbroblast populations (endothelial or epithelial cells). This
process can further disrupt the architecture and function of
the surrounding tissue.18 There was no evidence of epithe-
lial or endothelial mesenchymal transition in the form of co-
expression of epithelial markers such as E-cadherin or of
endothelial markers with ﬁbroblast markers, suggesting that
the ﬁbroblasts were most likely not of primary epicardial
origin.19,20 We did however ﬁnd an increase in cells co-
expressing SMA and FSP1, a marker for proliferating
myoﬁbroblasts, along with co-expression of TGF-b1, sug-
gesting that these myoﬁbroblasts originated from tissue-
speciﬁc ﬁbroblasts that were induced by TGF-b1. An
important aspect of this form of ﬁbrosis unlike replacement
ﬁbrosis is the potential for reversibility once the stress is
removed. A recent seminal article reported that introduction
of cardiac differentiation factors into mouse hearts promotedThe American Journal of Pathology - ajp.amjpathol.orgtransdifferentiation of ﬁbroblasts into cardiomyocytes,
highlighting the ability to alter ﬁbroblast cell fate by
providing appropriate transcription factors.21 This may
explain why the myoﬁbroblast population decreased after
TGF-b1 inhibition in our in vitro cell cultures. Although the
relatively extensive ﬁbrosis observed in severe HLHS may
not be reversible, our ﬁndings raise the interesting possi-
bility that TGF-b1 manipulation may have the potential to
reverse or reduce the progression of ﬁbrosis at least in
moderate HLHS. Besides its effect on ﬁbrosis, studies in
epithelial lineages have found that TGF-b1 induces cell
cycle arrest by increasing the expression of CDK inhibitors
and decreasing the expression of growth promoters, result-
ing in G1 arrest and premature senescence. To our knowl-
edge, ours is the ﬁrst study to demonstrate a similar
association of TGF-b1eassociated senescence and hypoxia
in human cardiac tissues and cells.
The ﬁnding that TGF-b1 can prevent DNA damage is an
exciting discovery. Cancer studies report that TGF-b1 can
either promote genomic stability or instability, depending on
the cellular context. In a normal cellular context with intact
p53 function, TGF-b1 contributes to competent DNA repair
and genomic stability. However, in cancers, TGF-b1
contributes to genomic instability.22 Our ﬁndings in injured
cardiac cells parallel the ﬁndings in cancers because TGF-
b1 up-regulation was associated with genomic instability,
whereas TGF-b1 inhibition promoted genomic stability as731
Figure 10 Effect of hypoxia on cell cycle arrest and in vitro tube
formation in ECs. A: HUVECs revealed an increase in cells in G1/S phase
(green and yellow) measured by DNA content quantiﬁcation using ﬂow
cytometry after hypoxia compared with controls. This increase was pre-
vented by treatment with SB431542. Representative plots are shown. B:
Hypoxia exposure causes a smaller increase in cell cycle arrest in G1/S
phase in SMCs derived from hPSCs compared with ECs. This increase was
again prevented by SB431542. C: The graph indicates the quantiﬁcation of
ECs and SMCs in the G1/S phase of cell cycle arrest. D: HUVECs exposed to
hypoxia had markedly reduced in vitro sprouting or tube formation
compared with SB431542-treated cells and controls. E: Tube formation was
graded and revealed reduced scores in hypoxic HUVECs compared with
controls and inhibitor-treated cells. *P < 0.05 versus controls; yP < 0.05
versus hypoxia (n Z 3 experiments in each group). Hyp, Hypoxia; Inh,
TGF-b1 inhibitor.
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732seen by reduced p53 activation and cell cycle arrest, thereby
rescuing cells from a senescent fate. Although this effect
may be detrimental in tumor cells, it appears to be a favor-
able response in cardiac cells by increasing the population
of cardiac lineages. Nonetheless, a direct association
between TGF-b1 and DNA damage response remains to be
explored.
The third important ﬁnding was the potentially detrimental
role of persistent HIF-1a up-regulation in fetal HLHS as
a mediator of hypoxic injury. It is important to distinguish
acute hypoxia (<24 hours) that transiently stabilizes HIF-1a
to permit activation of the downstream hypoxia response
machinery from persistent hypoxia that causes nuclear HIF-
1a stabilization and a paradoxical maladaptive response.23e25
In this regard, there is growing evidence of the detrimental
effects of chronic nuclear HIF1-a up-regulation on TGF-b1
activation and organ ﬁbrosis and on maladaptation to chronic
hypoxia at high altitudes in individuals with HIF1-a genetic
variants.18,26e28 A role for HIF-1a in cardiac malformations
has been reported before. Although some studies report HIF-
1a down-regulation with congenital heart defects,29 others
report that HIF-1a up-regulation is associated with cardiac
and neural tube defects.22 Our ﬁndings support the latter
possibility of the detrimental effect of chronic HIF-1a up-
regulation on cardiac growth and future investigations
should include a search for genomic defects in the HIF-1a
signaling pathway as a potential factor in increasing the
susceptibility of the fetal heart to genotoxic injury. Interest-
ingly, TGF-b1emediated DNA damage has been found in
previous studies in mouse embryo ﬁbroblasts to be inﬂuenced
by oxygen levels because TGF-b1einduced DNA damage
and senescence were partially rescued by normoxia.19 Our
study suggests that hypoxia-induced TGF-b1 activation may
be secondary to HIF-1a up-regulation.
The fourth novel ﬁnding was the susceptibility of vascular
ECs to hypoxia-mediated DNA damage evident in both fetal
HLHS and hPSC samples. In pure EC cultures of HUVECs,
we observed increased G1/S cell cycle arrest, an effect that
was less evident in a relatively pure SMC population.
Although hypoxia-induced G1/S cell cycle arrest has been
previously reported in other cell types,30,31 our study reports
the unique susceptibility of immature ECs to hypoxia-
induced cell cycle arrest, which is likely mediated by up-
regulation of G1 cell cycle inhibitors such as p16 and p18.
This ﬁnding differs from other studies that report increased
angiogenesis in vitro after acute hypoxic exposure of ECs
and may again reﬂect the differential effect of acute versus
chronic hypoxia, with the latter overwhelming natural
defense mechanisms, especially in the immature heart.30e32
A ﬁfth notable ﬁnding was the ability to recapitulate the
fetal HLHS phenotype in hPSCs subjected to prolonged
hypoxia during cardiac differentiation and to rescue this
phenotype with TGF-b1 inhibition. In our study, conditions
that mimicked fetal hypoxia resulted in a phenotype indis-
tinguishable from fetal HLHS. Because the process of cardiac
differentiation of hPSCsmimics the process of cardiogenesis,ajp.amjpathol.org - The American Journal of Pathology
Senescence in Fetal HLHShPSCs provide an excellent in vitro cellularmodel to study the
effect of prenatal factors during cardiac differentiation,
particularly because current cardiac differentiation protocols
yield cardiac lineages that are in fetal stages of maturity.4,5,14
Thus, our ﬁndings provide important biological insights
into LV growth failure in HLHS and explain why antenatal
and postnatal surgical interventions to relieve surgical
obstruction and to resect endocardial ﬁbrosis have met with
limited success in promoting ventricular growth.33,34 Lack
of knowledge of injury pathways has hindered the devel-
opment of medical therapies to promote ventricular growth
and prevent early and late ventricular dysfunction.35 Our
study suggests that the fetal growth and differentiation
pathways are reprogrammed possibly to permit survival in
an adverse environment but at the cost of organ growth and
that interventions aimed at ventricular growth may need to
be performed earlier before injury is irreversible and may
need to target not just ﬂow restoration but also the dysre-
gulated biological pathways in HLHS.
Conclusion
We identiﬁed the unique susceptibility of the fetal heart and
vasculature to DNA damage and premature senescence in
association with impaired cardiac differentiation and vas-
culogenesis. These ﬁndings underscore the ability of intra-
uterine stressors to cause fetal reprogramming with
deleterious consequences that can affect not only short-term
cardiac growth but also long-term cardiovascular function
and regenerative capacity. In addition, our ability to validate
the hPSC-derived cardiac stem cell system as a potentially
useful human in vitro cellular model to study signaling
defects in fetal stage cells may have implications for its use
in the study of environmental and teratogenic factors on
cardiac development.
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